Skip to main content

Advertisement

SpringerLink
Log in

Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Postoperative chemoradiotherapy (CRT) with concurrent 5-fluorouracil is the standard care for gastric cancer patients after curative surgery. The previous studies revealed that the subgroup of patients with high recurrence risk would benefit most from adjuvant CRT. S-1, a novel oral fluorouracil, has showed very effective in metastatic gastric cancer and became the standard option for gastric cancer with D2 dissection. The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated. This study is to determine the maximum tolerate dose (MTD) and dose-limiting toxicity (DLT) of S-1 given concurrently with postoperative high-dose radiotherapy in gastric cancer. Patients with more advanced stage (pT4 and/or pN+) after R0 resection were recruited. Eligible patients received one cycle standard SOX (S-1 plus oxaliplatin) chemotherapy, then S-1 monotherapy with concurrent radiotherapy for 6 weeks, followed by additional three cycles of SOX. During the concurrent CRT, S-1 was administered on every radiotherapy treatment day according to a predefined dose-escalation schedule. Radiotherapy (3D-RT or IMRT) was given to a total dose of 50.4 Gy in 28 fractions. DLT was defined as grade 3 or 4 hematologic and non-hematologic toxicity. From March 2011 to October 2012, 21 patients were enrolled at five dose levels: 40 (n = 3), 50 (n = 3), 60 (n = 6), 70 (n = 6) and 80 mg/m2/day (n = 3). D2-dissection was performed in 18 patients (85.7 %) and 15 patients (71.4 %) had stage III disease. The most common dose-related toxicity was anorexia, nausea and vomiting, fatigue and leucopenia. DLT was occurred in one patient at 60 mg/m2/day (grade 3 fatigue), one patient at 70 mg/m2/day (grade 3 vomiting and anorexia), two patients at 80 mg/m2/day (one with grade 3 vomiting and anorexia; another with grade 3 febrile leucopenia). Four patients did not complete CRT as planned. Overall, this phase I study demonstrated that postoperative CRT with daily S-1 was feasible in gastric cancer and the MTD of S-1 concurrent with radiotherapy was 70 mg/m2/day. This S-1-based postoperative CRT will be investigated in a multicenter phase III study in West China.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. He J, Chen WQ. Chinese Cancer Registry Annual Report, 2012. Beijing: Military Medical Science Press; 2012. p. 28–30.

    Google Scholar 

  2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.

    Article  CAS  PubMed  Google Scholar 

  3. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  4. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.

    Article  CAS  PubMed  Google Scholar 

  5. NCCN Guideline Panel National Comprehensive Cancer Network Guidelines in Oncology (NCCN Guidelines) Gastric cancer 2013;Version 2.

  6. Kozak KR, Moody JS. The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys. 2008;72:517–21.

    Article  PubMed  Google Scholar 

  7. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11:127–39.

    Article  CAS  PubMed  Google Scholar 

  8. Japanese gastric cancer treatment guidelines. ver. 3. Gastric Cancer. 2010;2011(14):113–23.

    Google Scholar 

  9. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.

    Article  CAS  PubMed  Google Scholar 

  10. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.

    Article  CAS  PubMed  Google Scholar 

  11. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  CAS  PubMed  Google Scholar 

  12. Huang J, Cao Y, Wu L, Liao C, He Y, Gao F. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis. Med Oncol. 2011;28:1004–11.

    Article  CAS  PubMed  Google Scholar 

  13. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  14. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.

    Article  CAS  PubMed  Google Scholar 

  15. Fukushima M, Satake H, Uchida J, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693–8.

    CAS  PubMed  Google Scholar 

  16. Harada K, Kawaguchi S. Supriatno, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40:713–9.

    Article  CAS  PubMed  Google Scholar 

  17. Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A. Postoperative chemoradiotherapy in gastric cancer−a phase I–II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol. 2010;21:530–4.

    Article  CAS  PubMed  Google Scholar 

  18. Jansen EP, Boot H, Saunders MP, et al. A phase I–II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 2007;69:1424–8.

    Article  CAS  PubMed  Google Scholar 

  19. Wang X, Jin J, Li YX, et al. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol. 2014;20:1067–73.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Wang X, Wang Y, Qiu M, et al. Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Med Oncol. 2011;28(Suppl 1):S274–9.

    Article  PubMed  Google Scholar 

  21. Lee DJ, Sohn TS, Lim do H, et al. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol. 2012;69:1333–8.

    Article  CAS  PubMed  Google Scholar 

  22. Eguchi H, Nagano H, Kobayashi S, et al. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemother Pharmacol. 2014;73:309–15.

    Article  CAS  PubMed  Google Scholar 

  23. Ohnishi K, Shioyama Y, Nakamura K, et al. Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. J Radiat Res. 2011;52:47–53.

    Article  PubMed  Google Scholar 

  24. Wada H, Nemoto K, Nomiya T, et al. A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer. Int J Clin Oncol. 2013;18:273–8.

    Article  CAS  PubMed  Google Scholar 

  25. Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. ‘Real’ 5-year survival rates and mortality rates in a country with high incidence. Dig Surg. 1998;15:317–22.

    Article  CAS  PubMed  Google Scholar 

  26. Gunderson LL. Gastric cancer–patterns of relapse after surgical resection. Semin Radiat Oncol. 2002;12:150–61.

    Article  PubMed  Google Scholar 

  27. Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2013;18:1013–21.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

    Article  CAS  PubMed  Google Scholar 

  29. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.

    Article  CAS  PubMed  Google Scholar 

  30. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63:1279–85.

    Article  PubMed  Google Scholar 

  31. Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84:e585–92.

    Article  CAS  PubMed  Google Scholar 

  32. Park SH, Sohn TS, Lee J, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015.

  33. Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361–6.

    Article  CAS  PubMed  Google Scholar 

  34. Li Q, Li G, Palmer JD, Zhang Z. Lymph node burden as a predictive factor for selective chemoradiotherapy in patients With locally advanced gastric cancer after a D2 dissection: a retrospective study. Am J Clin Oncol. 2014.

  35. Milano MT, Garofalo MC, Chmura SJ, et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol. 2006;79:497–503.

    Article  CAS  PubMed  Google Scholar 

  36. Leong T, Willis D, Joon DL, Condron S, Hui A, Ngan SY. 3D conformal radiotherapy for gastric cancer−results of a comparative planning study. Radiother Oncol. 2005;74:301–6.

    Article  PubMed  Google Scholar 

  37. Soyfer V, Corn BW, Melamud A, et al. Three-dimensional non-coplanar conformal radiotherapy yields better results than traditional beam arrangements for adjuvant treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 2007;69:364–9.

    Article  PubMed  Google Scholar 

  38. El-Hossiny HA, Diab NA, El-Taher MM. A Comparative Dosimetric Study of Adjuvant 3D Conformal Radiotherapy for Operable Stomach Cancer Versus AP-PA Conventional Radiotherapy in NCI-Cairo. J Egypt Natl Canc Inst. 2009;21:197–202.

    PubMed  Google Scholar 

  39. Minn AY, Hsu A, La T, et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010;116:3943–52.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Author notes

    Authors and Affiliations

    1. Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China

      Meng Qiu, Xing-chen Peng, Feng Bi, Xin Wang, Qiu Li, Feng Xu, Zhi-ping Li, Ya-li Shen, Ji-yan Liu, Ya-qing Zhao, Dan Cao, Hong-feng Gou, Yu Yang, Ye Chen & Cheng Yi

    Authors
    1. Meng Qiu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Xing-chen Peng
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Feng Bi
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xin Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Qiu Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Feng Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Zhi-ping Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Ya-li Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Ji-yan Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Ya-qing Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Dan Cao
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Hong-feng Gou
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Yu Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. Ye Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    15. Cheng Yi
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Meng Qiu.

    Additional information

    Meng Qiu and Xing-chen Peng have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Qiu, M., Peng, Xc., Bi, F. et al. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. Med Oncol 32, 191 (2015). https://doi.org/10.1007/s12032-015-0635-6

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1007/s12032-015-0635-6

    Keywords

    Search

    Navigation